ATRIUM HEALTH, WAKE FOREST BAPTIST HEALTH, WAKE FOREST SCHOOL OF MEDICINE AND RENALYTIX PARTNER TO ADVANCE KIDNEY HEALTH Partnership marks a long-term commitment to reducing impact of kidney disease in large populations via integration of earlier risk assessment paired with comprehensive disease management NEW YORK, CHARLOTTE AND WINSTON-SALEM, N.C., May, 19 2021 Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), Atrium Health, Wake Forest Baptist Health and Wake Forest School of Medicine announced a partnership to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The KidneyIntelX bioprognostic platform for early-stage diabetic kidney disease risk assessment will be available through Atrium Health s electronic health record (EHR) system, providing acces
Winsford, UK - 30 April 2021: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that the Annual Report and Accounts for the year ended 31 December 2020 and Notice of Annual General Meeting were posted to shareholders today and are available on the Investor Relations section of the Group s website. Annual General Meeting The Board continues closely to monitor the coronavirus pandemic and our priority at this time remains the health, safety and well-being of all of our stakeholders. As part of its monitoring, the Board has noted, in particular, the gradual easing of public health restrictions across England in line with the government s COVID-19 Response - Spring 2021 roadmap published in February 2021.
Tel: +44 (0) 20 7597 5970 Daniel Adams / Gary Clarence / Patrick Robb AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand
®, RESORBA
®, and LiquiBandFix8
®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal
® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France. In 202
Brisbane radio ratings: Nova loses its overall lead as Kate, Tim & Joel drop in drive
April 15, 2021 10:16
Nova 106.9 has lost its lead in Brisbane after experiencing a 0.8 point drop in its overall share, falling to third in the market on a 10.6% share. B105 surged to the front of the market after a 0.9 point gain took the Southern Cross Austereo (SCA) network to an 11.1% share.
Nova’s slip in the current survey – which ran from 7 February to 3 April – reflects drive juggernaut Kate Ritchie, Tim Blackwell and Joel Creasey losing another 1.5 points on top of the 1.1 points they dropped in survey one. The trio now hold a 13.3% share and are still the market leaders in the slot, followed by B105’s Carrie Bickmore and Tommy Little on 11% – after a gain of 0.8 points.
surrounding a comprehensive panel of novel biomarkers in kidney disease NEW YORK, April 14, 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announced today that it has entered into an exclusive option agreement with Joslin Diabetes Center for patent filings on certain additional novel biomarkers in kidney disease for development and deployment in the KidneyIntelX in vitro prognostic platform. These novel biomarkers have the potential to provide additional clinical utility for understanding early disease progression and risk of kidney failure, therapeutic response, and the mechanistic pathways of kidney disease beyond the inflammatory and tubular injury markers that are currently captured by KidneyIntelX. RenalytixAI plans to begin evaluating these novel biomarkers in expanded clinical validation studies beginning in the second half of 2021.